KVUE Stock Analysis — Kenvue
Sector: Consumer staples
AI Verdict
Kenvue trades at 15.8x next year's earnings while expected to deliver 41.0% EPS growth, making it cheap for the growth you're getting if its brand moat keeps driving results.
Competitive Moat
Kenvue owns household brands like Tylenol, Listerine, and Band-Aid, giving it shelf-space dominance and habitual consumer loyalty. Its moat is reinforced by brand recognition and distribution scale that new entrants struggle to match.
Summary
Kenvue's forward P/E of 15.8x with 41.0% expected EPS growth stands out in the consumer staples sector.
Where It Stands
Shares are down -7.44% over the past year, trade at 15.8x next year's earnings versus a sector median of 20x, and the trailing P/E of 22.2x is set to drop sharply if growth materializes.
Key Metrics
- Trailing P/E: 22.2x
- Forward P/E: 15.8x
- PEG Ratio: 0.53
- Earnings Growth: +0.4%
- Revenue Growth: +0.0%
- Market Cap: $36.8B
- 1-Year Return: -7.44%
- 52-Week High: $20.82
- 52-Week Low: $14.02
Analyst Consensus
6 Buy · 14 Hold · 0 Sell (20 analysts)
Bull Case
With analysts forecasting 41.0% EPS growth and a forward P/E of 15.8x, you're getting a rare growth profile at a discount to the sector's 20x median.
Bear Case
If the P/E reverts to the sector median of 20x without delivering on 41.0% EPS growth, the stock could see further downside after its -7.44% 1-year return.
Catalyst to Watch
Watch upcoming earnings for confirmation that EPS growth is tracking toward the 41.0% analyst consensus.